Although the Mycobacterium avium complex represents a clinically significant group of opportunistic pathogens in AIDS patients, the lack of information regarding their pathogenicity has generated a critical scientific void that makes it difficult to treat infections involving these organisms. Recent investigations have suggested that the M. avium complex, or products derived from the organisms, can somehow modify or suppress immunological functions important in the host response. Because the serovar specific glycopeptidolipid antigens (GPL) represent a common feature among M. avium serovars, they have been the focus of research in this laboratory for the last several years. The GPL have successfully been internally radiolabeled and used to investigate postphagocytic events associated with these components. Recently, we have shown that the major lipopeptide fragment of the GPL (beta-lipid), obtained by beta- elimination of the oligosaccharide determinant, is immunosuppressive to mitogen-induced lymphoproliferative response of mouse splenic lymphocytes. Ultrastructural analysis by electron microscopy indicates that the beta-lipid influences this immunosuppression by initial interaction with splenic monocytes/macrophage, that in turn leads to an internal disruption of cellular organization and possible modification of macrophage function. Because we have recently observed GPL degradation in mouse and human monocytes, we will continue to examine GPL degradation in an attempt to identify specific metabolic components that are immunosuppressive. Individual cell fractions will be assayed to identify specific cells that are affected by both GPL and beta-lipid. In addition, other M. avium lipopeptides, similar in structure to the beta-lipid, will be examined for their immunosuppressive properties.
Specific aims are: 1) to purify radiolabeled and nonradiolabeled lipids, 2) to investigate the degradation of GPL, 3) to examine the affect of the beta-lipid and GPL on mononuclear cells, and 4) to examine the effect of related lipopeptides on mononuclear cell responses. By defining the role of individual immunosuppressive M. avium lipids, we hope to obtain a composite analysis that can eventually be used to more clearly define mycobacterial pathogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI021946-08A2
Application #
2061647
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Project Start
1984-09-30
Project End
1997-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
8
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Southern Research Institute
Department
Type
DUNS #
006900526
City
Birmingham
State
AL
Country
United States
Zip Code
35205
Horgen, L; Barrow, E L; Barrow, W W et al. (2000) Exposure of human peripheral blood mononuclear cells to total lipids and serovar-specific glycopeptidolipids from Mycobacterium avium serovars 4 and 8 results in inhibition of TH1-type responses. Microb Pathog 29:16-Sep
Rastogi, N; Goh, K S; Horgen, L et al. (1998) Synergistic activities of antituberculous drugs with cerulenin and trans-cinnamic acid against Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 21:149-57
Barrow, W W (1997) Processing of mycobacterial lipids and effects on host responsiveness. Front Biosci 2:d387-400
Rastogi, N; Goh, K S; Van Ginkel, S Z et al. (1996) Identification of new drug targets in Mycobacterium avium and Mycobacterium tuberculosis. Res Microbiol 147:97-105
Wright, E L; Quenelle, D C; Suling, W J et al. (1996) Use of Mono Mac 6 human monocytic cell line and J774 murine macrophage cell line in parallel antimycobacterial drug studies. Antimicrob Agents Chemother 40:2206-8
Riviere, M; Puzo, G; Wright, E L et al. (1996) A unique phenylalanine-containing lipopeptide isolated from a rough-colony variant of Mycobacterium avium. Eur J Biochem 241:682-90
Wright, E L; Zywno-van Ginkel, S; Rastogi, N et al. (1996) Monoclonal infection involving Mycobacterium avium presenting with three distinct colony morphotypes. J Clin Microbiol 34:2475-8
Barrow, W W; Davis, T L; Wright, E L et al. (1995) Immunomodulatory spectrum of lipids associated with Mycobacterium avium serovar 8. Infect Immun 63:126-33
Rastogi, N; Goh, K S; Wright, E L et al. (1994) Potential drug targets for Mycobacterium avium defined by radiometric drug-inhibitor combination techniques. Antimicrob Agents Chemother 38:2287-95
Barrow, W W; de Sousa, J P; Davis, T L et al. (1993) Immunomodulation of human peripheral blood mononuclear cell functions by defined lipid fractions of Mycobacterium avium. Infect Immun 61:5286-93

Showing the most recent 10 out of 22 publications